Pharmacy Times

DECEMBER 11, 2023

The pharmacist can help patients to manage symptoms throughout the entire treatment journey.

Management 52

Management Patients 52

Pharmaceutical Technology

NOVEMBER 13, 2023

An upcoming two-day event will host talks on the impact of new technology on oncology trials and smaller biotechs.

52

52

PM360

JUNE 26, 2023

As oncology treatments become more targeted and personalized, oncologists’ opportunity to prescribe new treatments in a particular area stretches from monthly to quarterly to annually. Repetition Second, for oncology brands to be memorable, repetition is critical. We need to stop thinking of congresses as one-off events.

Marketing 97

Marketing Patients Medical Medicine 97

Storyvine

FEBRUARY 2, 2023

ASCO is a great opportunity to reconnect with colleagues, show off your brand and discover what’s new in cutting edge oncology research. With our easy-to-use platform, you can have an unbranded or branded video ready for review within minutes – perfect for posting while you're still at the event. Interested?

Doctors 94

Doctors Sales Management Media Competition 94

European Pharmaceutical Review

OCTOBER 18, 2022

The ZUMA-7 study demonstrated that treated patients had a four-fold greater improvement in the primary endpoint of event-free survival over the current SOC (8.3 3 cytokine release syndrome (CRS) and neurologic events were observed in 6 percent and 21 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred.

Side effects 106

Side effects Safety Patients Medical 106

European Pharmaceutical Review

JANUARY 10, 2024

“It is early, but we saw some promising results that this vaccine may help many of these patients avoid relapse, which could increase survival,” principal investigator Dr Shubham Pant, Associate Professor of Gastrointestinal Medical Oncology, explained. “It It also showed a favourable safety profile, which is exciting.”

Specialization 92

Specialization Patients Training Safety 92

pharmaphorum

SEPTEMBER 30, 2022

Genetic testing has become vastly more accessible in the last 20 years and has opened all kinds of doors in medicine, from pharmacogenetics and better understanding drug interactions and adverse events to tremendous advances in oncology: understanding the underlying genetics of cancer cells has allowed delivery of affective, targeted treatments.

Medicine 93

Medicine Patients 93

Pharmaceutical Technology

AUGUST 8, 2022

Time to progression in pain, castration-resistant prostate cancer, first symptomatic skeletal event, the commencement of successive anticancer treatment, all analysed at 12?week week intervals, as well as adverse events (AEs) as a measure of safety and tolerability were the trial’s secondary endpoints.

Food and Drug Administration 98

Food and Drug Administration FDA Safety Food 98

European Pharmaceutical Review

JUNE 6, 2023

These results were presented in an abstract at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Adverse events at Grade 3 or higher from all causes occurred in 23 percent of patients in the TAGRISSO arm versus 14 percent in the placebo arm.

Safety 96

Safety Patients Pharmaceutical 96

European Pharmaceutical Review

FEBRUARY 15, 2023

The results suggest “that neoadjuvant nivolumab was safe in long-term follow-up,” commented Patrick Forde, MBBCh, an Associate Professor of oncology and Director of the Thoracic Oncology Clinical Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Neoadjuvant nivolumab did not lead to surgical delays.

Food and Drug Administration 93

Food and Drug Administration Patients Food Networking 93

pharmaphorum

DECEMBER 8, 2022

See the complete 2023 event guide here. Our line-up of 20+ industry leading expert speakers includes: Vicky Appleman , STING Discovery Lead (Principal Scientist), Takeda Oncology. James Palacino , Vice President, Head of Biology, Orum Therapeutics. Oxana Beskrovnaya , Chief Scientific Officer, Dyne Therapeutics.

Leads 52

Leads Pharma Manufacturing Medical 52

Impetus Digital

MARCH 8, 2023

Well, wonder no more – we asked an AI software to explain how oncology brand teams can leverage our platform and services. Benefits of using the Impetus InSite Platform ® Oncology brand teams can reap significant benefits from using the Impetus InSite Platform®. What specific tools are useful for oncology brand teams?

Training 52

Training Patients Transportation Healthcare Provider 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

Soriot said AstraZeneca is particularly interested in oncology, cardiovascular disease, and rare diseases, and taking part in more ‘small to mid-size’ bolt-on acquisitions in the upcoming years. “We In this period, AstraZeneca has also taken part in five oncology and respiratory disease deals, respectively. billion in development.

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

European Pharmaceutical Review

NOVEMBER 7, 2022

“The FDA’s Breakthrough Designation recognises the potential of elranatamab as an innovative medicine for multiple myeloma (MM) which has relapsed or is refractory to existing treatments,” shared Dr Chris Boshoff, Chief Development Officer for Oncology and Rare Disease at Pfizer Global Product Development. Elranatamab clinical trial data.

Food and Drug Administration 100

Food and Drug Administration Medicine Safety FDA 100

pharmaphorum

MAY 27, 2022

With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized. Download the Full Event Guide here for speakers, presentations, pricing and more. The post 13th World Multispecifics Summit appeared first on.

Engineering 52

Engineering Manufacturing Patients 52

Pharmacy Times

MAY 9, 2023

FCS president and managing physician Lucio Gordan, MD, is a featured speaker at nationwide oncology event to discuss how genetics are advancing cancer care.

Physicians 26

Physicians Management 26

pharmaphorum

NOVEMBER 11, 2022

Download the full event guide here for the official agenda. Marc Pelletier , Senior Principal Scientist – Translational Immune Oncology, Novartis. Download your event guide to see what these experts will be discussing. Alan Watt , Chief Scientific Officer, NodThera.

Medicine 52

Medicine Medical Leads Pharma 52

European Pharmaceutical Review

DECEMBER 14, 2022

Adverse events observed with mRNA-4157/V940 in KEYNOTE-942 were consistent with those previously reported in a Phase I clinical trial. Serious treatment-related adverse events (SAEs) occurred in 14.4 Safety data from the Phase IIb trial assessing an mRNA cancer vaccine plus KEYTRUDA ®.

Safety 112

Safety Patients Medical Pharmaceutical 112

European Pharmaceutical Review

AUGUST 17, 2022

The incidence of adverse events, including those of grade 3 or higher, during treatment was higher in the lutetium ( 177 Lu) vipivotide tetraxetan plus SOC group than in the SOC only group11. The most common treatment-emergent adverse events in those receiving lutetium ( 177 Lu) vipivotide tetraxetan plus SOC (all grades) were fatigue (43.1

Medicine 117

Medicine Patients Consulting Marketing 117

Pharmaceutical Technology

JUNE 4, 2023

At the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting, being held 2–6 June, new data was presented from the randomized, controlled Phase III KEYNOTE-671 study of MSD’s Keytruda (pembrolizumab) (abstract LBA100). months, the two-year event-free survival (EFS) was 62.4% At a median duration of follow-up of 25.2

Distribution 75

Distribution Recruitment Patients Marketing 75

pharmaphorum

DECEMBER 22, 2022

The results were published in the New England Journal of Medicine Evidence , as well as presented at the European Society for Medical Oncology Congress 2022. The updated results showed that the Imfinzi combination reduced risk of death by 24% compared to chemotherapy alone after an additional 6.5

Medicine 64

Medicine Patients Safety Medical 64

pharmaphorum

JANUARY 5, 2023

During The Economist’s 8th Annual World Cancer Series congress in Brussels November last year, web editor Nicole Raleigh sat down to discuss the event and its themes with Greg Rossi, senior vice president, head of oncology Europe and Canada at AstraZeneca.

Patients 52

Patients Physicians Management 52

Pharmaceutical Technology

APRIL 4, 2023

Dr Robert Casero and Dr Tracy Murray Stewart, both belonging to the oncology section of the Johns Hopkins University School of Medicine, will lead the research. The partners will also focus on the further evaluation of ivospemin’s mechanism of action, as well as its potential combination with CPP-1X and standard of care agents.

Medicine 59

Medicine FDA Leads Patients 59

Pharma Marketing Network

JULY 21, 2023

Some relevant groups to join include: Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Innovation Organization (BIO), and American Society of Clinical Oncology (ASCO). Attending events is a great way to make new connections and to position yourself as a thought leader in your field.

Pharmaceutical 52

Pharmaceutical Sales Networking Pharmaceutical research 52

PM360

DECEMBER 14, 2023

But we also feature exciting progress in drug delivery technology, vaccine development, precision oncology, at-home ultrasounds, value-based care contracting, IV monitoring, and other innovations changing how our industry operates to ultimately better serve patients.” Register for the event at: [link].

Insurance 64

Insurance Marketing Healthcare Healthcare 64

European Pharmaceutical Review

FEBRUARY 22, 2023

“Today’s approval offers physicians and patients in the EU more flexibility to determine the right treatment plan and enables more patients to potentially benefit from this medicine,” explained Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Business Unit.

Safety 90

Safety Medicine Physicians Food 90

European Pharmaceutical Review

OCTOBER 17, 2022

The most common adverse events (all grades) in the Pluvicto ® part of the study were fatigue, dry mouth, nausea, anaemia (low red blood cell counts), decreased appetite and constipation.

Medicine 122

Medicine Patients Medical Pharmaceutical 122

PM360

MARCH 24, 2023

Franchise Head for Immuno-oncology and Gastrointestinal Tumors at AstraZeneca. “We Impacts of Self-care Education on Adverse Events and Mental Health Related Quality of Life in Breast Cancer Patients Under Chemotherapy.” Self-care help (24%) and guidance for spouses and caregivers (22%) were the next two most-requested resources.

Patients 98

Patients Education Side effects Media 98

European Pharmaceutical Review

SEPTEMBER 13, 2022

Results presented at the European Society for Medical Oncology Congress (ESMO) reveal that, regardless of the treatment group, all 22 patients who had not received previous immune checkpoint inhibitor therapy responded to the investigational combination therapy, with 41 percent having a complete response.

Patients 79

Patients Medical Pharmaceutical 79

pharmaphorum

SEPTEMBER 22, 2022

Read on to find out about unlocking the potential of connected commercialisation solutions, what HCPs want from post-pandemic communication, achieving launch excellence in oncology and much more. Achieving launch excellence in oncology. A successful launch in the oncology space is not guaranteed; it is strategically planned and earned.

Pharma 52

Pharma Marketing Pharmaceutical Physicians 52

pharmaphorum

DECEMBER 2, 2022

Read on for key stories from this year’s Frontiers Health conference in Italy, unlocking the promise of patient support programmes in oncology, supercharging communications with modular content, and much more. Nicole Raleigh rounds up key highlights from the event. Unlocking the promise of patient support programmes in oncology.

Healthcare 52

Healthcare Healthcare Pharma Marketing 52

European Pharmaceutical Review

NOVEMBER 17, 2022

The most frequent treatment-emergent adverse events (TEAEs) in patients treated with Zolbetuximab plus mFOLFOX6 were nausea, vomiting, and decreased appetite. “I Other secondary measures were objective response rate, duration of response, safety and tolerability and quality-of-life parameters.

Safety 82

Safety Patients Pharma Pharmaceutical 82

pharmaphorum

DECEMBER 8, 2022

Download the event guide here to view the full programme with 80+ industry-leading speakers. Clinical Lessons : Be the first to hear industry-changing clinical results from Exelixis , Oxford Biotherapeutics , Daiichi Sankyo , Shanghai Miracogen , ImmunoGen , and Elucidia Oncology.

Specialization 52

Specialization Manufacturing Engineering Networking 52

pharmaphorum

NOVEMBER 8, 2022

Trial results showed that pembrolizumab met both primary endpoints of event-free survival and pathological complete response. Previously, there was no immunotherapy treatment option available for people with early stage or locally advanced TNBC, creating an unmet need for these patients,” said David Long, head of oncology at MSD UK.

Patients 97

Patients Leads Pharma 97

Pharmaceutical Technology

JANUARY 2, 2023

According to GlobalData, the latest event to affect Lifirafenib maleate’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway. BeiGene overview BeiGene is a biotechnology company.

Specialization 40

Specialization Pharmaceutical Medicine Patients 40

pharmaphorum

AUGUST 25, 2022

Explore approaches to boost safe gene-editing, approach regulatory affairs, turbocharge scale-up, optimize analytics and more to produce best-in-class therapies for immuno-oncology and regenerative medicine. Find out more and check out the full agenda in the Event Guide: Download the event guide.

Engineering 40

Engineering Medicine Safety Manufacturing 40

pharmaphorum

JANUARY 29, 2019

As cancer is understood increasingly not by type, or even tumour type but specific mutation the era of personalised oncological therapies is visible. this free to attend event will cover a number of topics critical to the future of oncology including: •The changing face of cancer: how do we define it now?

Medicine 52

Medicine Patients 52